Two Blokes

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data

  • click to rate
    Posted by Two Blokes Jul 3 - Filed in Stock - 5 views
    Aldeyra Therapeutics' Reproxalap is now on its third NDA, which was filed in June 2025. It supposedly fixes prior trial flaws. ALDX believes a potential FDA acceptance could set a PDUFA date for December 2025. After that, AbbVie may pay $100 million upfront and share US profits if Reproxalap wins approval, which should materially de-risk its eventual commercialization.